Patent Classification

Drug Delivery System, Antigen/Vaccine/Hormone/Antibody

1. Human lymphocyte vaccine adjuvant
    
2. Methods and compositions for live attenuated viruses
    
3. Use of bacterium for manufacture of a vaccine
    
4. Encapsulated vaccines for the oral vaccination and boostering of fish and other animals
    
5. Methods for antibody engineering
    
6. Attenuated salmonella SP12 mutants as antigen carriers
    
7. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
    
8. Attenuated gram negative bacteria
    
9. Flexible vaccine assembly and vaccine delivery platform
    
10. Prostate cancer vaccine
     
11. Method for producing the flu virus
     
12. Cysteine engineered antibodies and conjugates
     
13. Antibiotic resistance free vaccines and methods for constructing and using same
     
14. Modified free-living microbes, vaccine compositions and methods of use thereof
     
15. Delivery vehicle composition and methods for delivering antigens and other drugs
     
16. CpG DNA adjuvant in avian vaccines
     
17. Antibody fusion proteins: effective adjuvants of protein vaccination
     
18. Edible vaccines expressed in soybeans
     
19. Recombinant parainfluenza virus expression systems and vaccines
     
20. Intranasal vaccine for use against disease caused by enterotoxigenic Escherichia coli
     
21. Adjuvant viral particle
     
22. Assay for the separation and quantification of hemagglutinin antigens
     
23. Insertion sites in fowlpox vectors
     
24. Settings for recombinant adenoviral-based vaccines
     
25. Use of microparticles with adsorbed antigen to stimulate immune responses
     
26. Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
     
27. Use of cross-protection to identify novel vaccine candidates for infectious agents
     
28. Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
     
29. Proteosome-liposaccharide vaccine adjuvant
     
30. Synthetic lipid-a-analogs and uses thereof
     
31. DNA vaccine compositions and methods of use
     
32. Non-toxic mucosal adjuvant
     
33. Polyvalent conjugate vaccine for cancer
     
34. Isolated avian cell that expresses Vaccinia virus host range genes
     
35. Yeast-based vaccines as immunotherapy
     
36. Adenovirus formulations
     
37. Immunogenic complex
     
38. Attenuated gram negative bacteria
     
39. Use of vaccinia virus deleted for the E3L gene as a vaccine vector
     
40. Vaccine composition of surfactants as adjuvant of immunity
     
41. Transgenic plant-based vaccines
     
42. Heat shock protein-based vaccines and immunotherapies
     
43. Modified CpG oligodeoxynucleotide with improved immunoregulatory function
     
44. Carrier protein having an adjuvant effect
     
45. Multivalent vaccine composition having increased stability of capsular polysaccharide
     
46. Flagellin-based adjuvants and vaccines
     
47. Proteosome influenza vaccine
     
48. Adjuvants for use in vaccines
     
49. Method of preparing a modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity
     
50. Recombinant viral-based malaria vaccines
     
51. Immuno-modulating effects of chemokines in DNA vaccination
     
52. Combined DNA vaccine and biological modifiers for cancer therapy
     
53. Subunit vaccine against respiratory syncytial virus infection
     
54. Adjuvant systems and vaccines
     
55. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
     
56. Vaccine against cancer diseases that are associated with the her-2/neu oncogene
     
57. Regulated antigen delivery system (RADS)
     
58. Membrane virus host range mutations and their uses as vaccine substrates
     
59. Vaccine compositions including chitosan for intranasal administration and use thereof
     
60. Molecular vaccine linking intercellular spreading protein to an antigen
     
61. Influenza vaccine composition
     
62. Cationic lipid-mediated enhancement of nucleic acid immunization of cats
     
63. Nanoemulsion vaccines
     
64. Nanoparticle vaccines
     
65. DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
     
66. Mucosal DTPa vaccines
     
67. Live genetically attenuated malaria vaccine
     
68. Polynucleotide encoding a mutated HIV gp41 polypeptide
     
69. Tumor vaccines
     
70. Method of removing endotoxin from vaccines
     
71. Enveloped virus vaccine and method for production
     
72. Anti-CD40 monoclonal antibody
     
73. Peptide-based vaccine for influenza
     
74. Attaching substances to micro-organisms
     
75. Process for preparing conjugate vaccines and the conjugate vaccines
     
76. Histamine receptor antibody
     
77. Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
     
78. Adjuvant-containing vaccines
     
79. Attenuated human rotavirus vaccine
     
80. Plasmid maintenance system for antigen delivery
     
81. Urogenital or anorectal, transmucosal vaccine delivery system
     
82. Methods for enhancing the production of viral vaccines in cell culture
     
83. Streptococcus pneumoniae proteins and vaccines
     
84. Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
     
85. Multivalent antibody constructs
     
86. Production of humanized antibodies in transgenic animals
     
87. Immunstimulating lipid formulation
     
88. Live genetically attenuated malaria vaccine
     
89. Microfluidized oil-in-water emulsions and vaccine compositions
     
90. Smallpox vaccine
     
91. Attenuated Salmonella strain used as a vehicle for oral immunization
     
92. Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
     
93. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
     
94. Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
     
95. Modified vaccinia virus ankara for the vaccination of neonates
     
96. Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
     
97. Inactivated respiratory syncytial viral vaccines
     
98. Nontoxic mucosal adjuvant
     
99. Hybrid LT-A/CT-B holotoxin for use as an adjuvant
     
100. Live vaccines for allergy treatment
      
101. Glucosyltransferase immunogens
      
102. Inactivated influenza virus vaccine for nasal or oral application
      
103. Adjuvant for transcutaneous immunization
      
104. Method for generating influenza viruses and vaccines
      
105. Immunostimulatory oligonucleotides and uses thereof
      
106. DNA vaccination for treatment of autoimmune disease
      
107. Mycobacterium tuberculosis immunizationg
      
108. Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
      
109. Anti-sepsis conjugate vaccine
      
110. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
      
111. Melanoma vaccine and methods of making and using same
      
112. Control of acidosis
      
113. Method for producing monoclonal antibodies
      
114. Recombinant poxviruses having foreign DNA expressed under the control of poxvirus regulatory sequences
      
115. Hepatitis A vaccines
      
116. Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization
      
117. Vaccine for the prevention of bacterial infection of the bovine mammary gland
      
118. Vaccine immunotherapy for immune suppressed patients
      
119. Avian pneumovirus vaccine
      
120. Process for producing humanized chimera antibody
      
121. Predictive assay for immune response
      
122. Oral vaccinia formulation
      
123. Polysaccharide-polypeptide conjugate
      
124. Vaccines absorbable by the transmucosal way
      
125. Monoclonal antibodies with reduced immunogenicity
      
126. Multi-stage cascade boosting vaccine
      
127. Vaccine composition comprising iron phosphate as vaccine adjuvant
      
128. Lawsonia intracellularis vaccine
      
129. Vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
      
130. Compositions for microencapsulation of antigens for use as vaccines
      
131. Feline calicivirus genes and vaccines in particular recombinant vaccines
      
132. Coccidial vaccine and methods of making and using same
      
133. Vaccines containing attenuated bacteria
      
134. Lyme disease vaccines
      
135. Vaccine against mumps containing a jeryl-lynn virus strain
      
136. Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A
      
137. Method for the isolation of polysaccharides
      
138. Formalin-treated human papillomavirus L1 protein vaccine
      
139. Streptococcus pneumoniae proteins and vaccines
      
140. Freeze-dried hepatitis A attenuated live vaccine and its stabilizer
      
141. Nucleic acid constructs
      
142. Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
      
143. Dermatomycosis vaccine
      
144. Vaccine formulations
      
145. Production method of recombinant rotavirus structural proteins and vaccine composition
      
146. Plant lectins as mucosal adjuvants
      
147. Inactivated influenza virus vaccine for nasal or oral application
      
148. Vaccines against Escherichia coli O157 infection
      
149. Vaccines containing ribavirin and methods of use thereof
      
150. Use of microparticles combined with submicron oil-in-water emulsions
      
151. Methods and interferon deficient substrates for the propagation of viruses
      
152. Plasmid-based vaccine for treating atherosclerosis
      
153. Method for the preservation of biologically-active material
      
154. Pneumococcal protein homologs and fragments for vaccines
      
155. Compositions and methods for generating chimeric heteromultimers
      
156. Recombinant multivalent malarial vaccine against Plasmodium falciparum
      
157. Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
      
158. Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
      
159. Multicomponent meningococcal vaccine
      
160. Vectors and methods for immunization or therapeutic protocols
      
161. Polynucleotide vaccine formula in particular against bovine respiratory pathology
      
162. Adjuvants for use in vaccines
      
163. Recombinant parainfluenza virus expression system and vaccines
      
164. Over-expressing homologous antigen vaccine and a method of making the same
      
165. Cellular vaccines and immunotherapeutics and methods for their preparation
      
166. Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
      
167. Method of delivering antigens for vaccination with a live vector
      
168. Method for making humanized antibodies
      
169. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
      
170. Adjuvant for a vaccine composition
      
171. Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
      
172. Heat shock protein-based vaccines and immunotherapies
      
173. Anthrax vaccine
      
174. Live attenuated bacteria for use in a vaccine
      
175. Immunogenic formulations comprising oil bodies
      
176. Fibrocyte-base vaccine formulations
      
177. Adjuvant comprising a lipopolysaccharide antagonist
      
178. Attenuated microorganisms for the treatment of infection
      
179. Enterococcus antigens and vaccines
      
180. Vaccine against lipopolysaccharide core
      
181. Method of making microencapsulated DNA for vaccination and gene therapy
      
182. Proteosome influenza vaccine
      
183. Peptide-based vaccine for influenza
      
184. Method for generating genetically altered antigens
      
185. Surface receptor antigen vaccines
      
186. Smallpox vaccine
      
187. Heat shock protein-based vaccines and immunotherapies
      
188. Compositions and methods for identifying antigens which elicit an immune response
      
189. Noninvasive genetic immunization, expression products therefrom, and uses thereof
      
190. Vaccination by topical application of genetic vectors
      
191. HIV vaccine
      
192. Methods for vaccination and vaccines therefor
      
193. Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
      
194. Methods for enhancing the production of viral vaccines in cell culture
      
195. Adjuvanted vaccine which is substantially free of non-host albumin
      
196. Hepatitus A virus vaccines
      
197. Invaplex from gram negative bacteria, method of purification and methods of use
      
198. Methods for enhancing the production of viral vaccines in cell culture
      
199. Tuberculosis vaccine
      
200. Stratified and cryogenically stored vaccines, process for their preparation
      
201. Microencapsulated DNA for vaccination and gene therapy
      
202. Methods for enhancement of protective immune responses
      
203. Serum-free, low-protein media for rotavirus vaccine production
      
204. Method for the development of an HIV vaccine
      
205. Adjuvant combinations for immunization composition and vaccines
      
206. Helper-free rescue of recombinant negative strand RNA virus
      
207. Inactivated influenza virus vaccine for nasal or oral application
      
208. Herpes simplex virus VP22 vaccines and methods of use
      
209. DNA immunization against chlamydia infection
      
210. Prophylactic and therapeutic monoclonal antibodies
      
211. Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
      
212. Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
      
213. Peptide immunogens for vaccination against and treatment of allergy
      
214. Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
215. Conjugate vaccine for nontypeable Haemophilus influenzae
      
216. Influenza vaccine
      
217. Avian pneumovirus vaccine
      
218. Rotavirus subunit vaccine
      
219. Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
      
220. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
      
221. Malaria vaccine
      
222. Stabilizing diluent for polypeptides and antigens
      
223. Temperature sensitive plasmids of P. haemolytica
      
224. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
      
225. Antibody specific for H4-1BB
      
226. Chemokine-tumor antigen fusion proteins as cancer vaccines
      
227. DNA vaccines against poxviruses
      
228. Vaccine compositions for mucosal delivery
      
229. Vaccines for the protection of cattle from psoroptic scabies
      
230. Artificial proteoglycans
      
231. Antigen carbohydrate compounds and their use in immunotherapy
      
232. Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
      
233. Vaccine comprising an iscom consisting of sterol and saponin which is free of additional detergent
      
234. Vaccine against mycobacterial infections
      
235. Live vaccine constituting minor risk for humans
      
236. Oral delivery of nucleic acid vaccines by particulate complexes
      
237. Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
      
238. DNA vaccine and methods for its use
      
239. Method to produce inactivated w/o emulsion adjuvated vaccines
      
240. Therapeutic using a bispecific antibody
      
241. Methods to improve immunogenicity of antigens and specificity of antibodies
      
242. Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer
      
243. Method for making humanized antibodies
      
244. Method of preservation of vaccines with polybiguanide
      
245. Vaccine compositions including chitosan for intranasal administration and use thereof
      
246. Influenza virus vaccine composition
      
247. Caulobacter LPS immunoadjuvants
      
248. Parapoxviruses containing foreign DNA, their production and their use in vaccines
      
249. Immunopotentiating formulations for vaccinal use
      
250. NANBV diagnostics and vaccines
      
251. Adjuvants for vaccines
      
252. Anti-cancer vaccine
      
253. Method of specifying vaccine components for viral quasispecies
      
254. Vaccine adjuvants
      
255. Streptococcus gordonii strains resistant to fluorodeoxyuridine
      
256. Production of virus and purification of viral envelope proteins for vaccine use
      
257. Staphylococcus aureus antigen-containing whole cell vaccine
      
258. Formulations of recombinant papillomavirus vaccines
      
259. Use of mCRP to enhance immune responses
      
260. Transdermal, hormone-delivering therapeutic system
      
261. Recombinant mycobacterial vaccine
      
262. Method of making microencapsulated DNA for vaccination and gene therapy
      
263. HIV-vaccines
      
264. DNA vaccines against tick-borne flaviviruses
      
265. Two-phase system for the production and presentation of foreign antigens in hybrid live vaccines
      
266. Concentrated antibody preparation
      
267. Compositions for preserving haptenized tumor cells for use in vaccines
      
268. Method of using mouse model for evaluation of HIV vaccines
      
269. Single-chain forms of the glycoprotein hormone quartet
      
270. Method of affinity cross-linking biologically active immunogenic peptides to antibodies
      
271. Multivalent and multispecific antigen-binding protein
      
272. DNA immunization against chlamydia infection
      
273. Recombinant immunogenic actinomycetale
      
274. Live in ovo vaccine
      
275. Oral administration of pneumococcal antigens
      
276. Vaccine compositions and methods of modulating immune responses
      
277. Adjuvant incorporation into antigen carrying cells: compositions and methods
      
278. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes
      
279. Method for the separation and purification of immunoglobulins
      
280. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
      
281. Carrier protein having an adjuvant effect, immunogenic complex containing it, process for their preparation, nucleotide sequence and vaccine
      
282. Oral immunization with transgenic plants
      
283. Complex of human growth hormone and zinc
      
284. Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
      
285. Cross-protective rotavirus vaccine
      
286. Methods for treating a fibrin encapsulated tumor using a fibrin specific monoclonal antibody and compositions used therein
      
287. DNA based vaccination of fish
      
288. Vaccine delivery system
      
289. Synthetic peptides for rubella vaccine
      
290. Process for the production of vaccines and their use
      
291. Synthetic peptides and vaccines comprising same
      
292. Multiassay method for determining the concentrations of antigens and interferants
      
293. Heat shock protein 70 preparations in vaccination against cancer and infectious disease
      
294. DNA vaccines against rotavirus infections
      
295. Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
      
296. Soluble herpesvirus glycoprotein complex vaccine
      
297. Vaccine adjuvant and vaccine
      
298. Human/simian chimeric hepatitis A virus vaccine
      
299. Influenza vaccine compositions
      
300. Helicobacter pylori proteins useful for vaccines and diagnostics
      
301. Wet granulation formulation of a growth hormone secretagogue
      
302. Hepatitis B surface antigen vaccine
      
303. DNA vaccines for eliciting a mucosal immune response
      
304. Oral vaccines
      
305. Vaginal suppository vaccine for urogenital infections
      
306. Coccidiosis poultry vaccine
      
307. Vaccine for induction of immunity to malaria
      
308. Vaccine adjuvant and vaccine
      
309. Multicomponent clostridial vaccines using saponin adjuvants
      
310. Vaccine adjuvant for immunotherapy of melanoma
      
311. Pulmonary delivery of active fragments of parathyroid hormone
      
312. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
      
313. Hepatitis B surface antigen vaccine
      
314. RNA respiratory syncytial virus vaccines
      
315. Stabilized thyroid hormone preparations and methods of making same
      
316. Stabilizers for lyophilized mumps vaccines
      
317. Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
      
318. Composition for sustained release of human growth hormone
      
319. Vaccines for equine influenza
      
320. HIV envelope polypeptides
      
321. Stabilized live vaccine
      
322. Vaccine
      
323. Intestinal protozoal vaccines
      
324. Vaccines expressed in plants
      
325. Mucosal immunogens for novel vaccines
      
326. Mucosal administration of pneumococcal antigens
      
327. Method for producing a bacterial vaccine and novel vaccines produced thereby
      
328. Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
      
329. Subunit respiratory syncytial virus vaccine preparation
      
330. Pharmaceuticals based on papillomaviruses
      
331. Pharmaceutical preparation containing human growth hormone
      
332. Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
      
333. Oral administration of pneumococcal antigens
      
334. Polymeric lamellar substrate particles for drug delivery
      
335. Pharmaceutical formulation
      
336. Self-adjuvanting peptide vaccine delivery system and production thereof
      
337. Stabilized live vaccine
      
338. Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
      
339. Compositions for the delivery of antigens
      
340. Submicron emulsions as vaccine adjuvants